AHSA1 Knockout HEK293T Polyclonal Cells comprise a heterogeneous population of HEK293T cells engineered via CRISPR/Cas9-mediated disruption of the AHSA1 gene, providing a loss-of-function model to interrogate the co-chaperone’s role in the Hsp90 chaperone cycle. This polyclonal knockout product maintains the native genetic background while ablating AHSA1 expression, enabling robust, population-level analyses of Hsp90-dependent cellular processes without the clonal artifacts associated with single-cell-derived lines. Suitable for transient and stable transfection applications, these cells retain the high transfectability of the parental HEK293T line, facilitating downstream genetic manipulation for pathway dissection or complementation studies.
The host HEK293T cell line is a widely utilized human embryonic kidney derivative that constitutively expresses the SV40 large T antigen, promoting episomal replication of plasmids containing the SV40 origin. This feature, combined with its rapid growth and amenability to calcium phosphate and lipid-based transfection, makes HEK293T a preferred system for high-level recombinant protein production, lentiviral packaging, and functional genomics screens. The endogenous presence of a functional Hsp90 chaperone machinery and diverse client proteins, including kinases and steroid hormone receptors, provides a physiologically relevant context for studying AHSA1 function.
AHSA1 encodes an activator of Hsp90 ATPase 1 (Aha1), a specialized co-chaperone that directly binds and stimulates the intrinsic ATPase activity of Hsp90, thereby accelerating the chaperone’s conformational cycle. This stimulation is critical for the efficient folding and maturation of Hsp90 client proteins, which include the kinases AKT and RAF, and steroid hormone receptors such as the androgen receptor and estrogen receptor. AHSA1 expression is transcriptionally induced by HSF1 in response to cellular stress, coupling chaperone activity to proteotoxic demands. Mechanistically, AHSA1 interacts with Hsp90 and client proteins during the ATP-driven cycle, promoting client release and functional stabilization; thus, its disruption is expected to decelerate chaperone-mediated folding, reduce client protein stability, and sensitize cells to Hsp90 inhibitors.
In the HEK293T context, ablation of AHSA1 creates a valuable cellular tool for dissecting the Hsp90 chaperone network and its role in oncogenic signaling and drug resistance. Given the line’s endogenous expression of Hsp90 clients, this knockout model enables direct assessment of AHSA1 dependency for client protein stability and activity, without the confounding effects of exogenous overexpression. Researchers can employ this system to validate AHSA1 as a potential cancer therapeutic target, examine compensation by other co-chaperones, or investigate how Hsp90 cycle kinetics influence signal transduction pathways that drive proliferation and survival.
Typical applications include immunoblotting to monitor the steady-state levels of Hsp90 client proteins following AHSA1 disruption, Hsp90 ATPase activity assays to quantify the biochemical impact of the knockout, and cell viability dose-response experiments with Hsp90 inhibitors (e.g., geldanamycin derivatives) to assess chemosensitization. Co-immunoprecipitation of Hsp90 complexes allows mapping of altered client interactions, while cycloheximide chase assays directly measure changes in protein half-life. These cells also support high-content screens for modulators of the chaperone cycle. For further information or custom requirements, please contact Ascent Research.
